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Chemotherapy of Liver Abscess (I). Significance of the 
Preoperative Administration of Amphotericin B 
Based on Concentration in the Liver Tissue 
HIROSHI TANIMURAl>, KATSUYOSHI TABUSE1>, KAZUNARI MoRr1>, NAKAHIRO SHIMOTSUMA1>, 
YAsuo KASANo1>, MrnoRu OcHrA11>, KEISUKE YosHIDA2>, NoBUAKI KoBAYASH12＞、
YosHIO YAMAOKA2>, YASUYUKI SHIMAHARA2>, KAZUE 0ZAWA2>, 
HIDEYO y AMAGUCHra>, KATSUHISA u CHIDA 4>and HrKARU KuME5) 
Department of Gastroenterological Surgery, Wakayama Medical College1>, Second Department of Surgery, 
Kyoto University School of Medicine2>, Institute of Applied Microbiology, University of Tokyo3l, 
Research Center for Medical Mycology, Teikyo University川， Departmentof 
Pathology, Kitasato University School of Medicines> 
The antifungal agent amphotericin B syrup was administered orally at a dose of 2,400 mg 
each time twice a day for 3 days preoperatively to 11 patients who underwent hepatectomy, and 
the concentrations in the serum, liver and spleen tissue, and gallbladder bile were measured to 
obtain basic data for the prevention and treatment of fungal liver abscess. 
1) The concentration of amphotericin B in serum four hours after the五naladministration on 
the 3rd day was 0.08土0.02μ.g/ml. On the day of the operation, it was 0.09士0.04μ.g/ml even 
though it was 20 hours after administration, and it was evident that the concentration in serum 
is maintained over long periods. 
2) The concentration in the liv巴rtissue and bile were 0.52士0.18μ,g/g (maximum 1.00 μ,g/g) 
and 1.20土0.55μ,g/ml (maximum 1.95 μ,g/ml), respectively. These values wer巴 5ふfoldand 
13.3-fold the serum levels, respectively. The concentration in the gallbladder wall (two cases) 
Key words: Amphotericin B, Liver, Spleen, Bile Concentration. 
索引語：アムホテリシンB，肝組織内濃度，牌組織内濃度，胆汁中濃度．
Present address: Department of Gastroenterological Surgery, Wakayama Medical College, 7-Bancho 27, 
Wakayama, 640, Japan. 
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was 1.09, 0必μ，g/gand that in the spleen tissue (one C邸巴） was 0.56 μ,g/g. Aft巴roral admin-
istration, there were high concentrations in the liver, gallbladder wall and spleen tissu巴which
SU伍cientlyexceeded the MICso of candi"da. 
3) There were no side effects or abnormal laboratory test valu巴din any of patients. 
From these results, it was evident that oral administration of large doses of amphotericin 
B results in higher concentrations in the serum, liver, gallbladder and spleen tissue and bile at 
an earlier stage than with intravenous administration, and administration of this drug is also 








中濃度は 0.08±0. 02 μg/mlであり，手術日は投与
20時間後にも拘らず， 0.09±0. 04 μg/mlと，血中濃
度は長時間にわたって持続していた．
2）肝組織内，胆汁中濃度はそれぞれ0.52±0.18μ,g/
g （最高1.00 μg/g), 1. 20土0.55 μg/ml （最高1.95 
μg/ml）であり，血中濃度のそれぞれ5.8倍， 13.3倍
の濃度であり，また，胆嚢壁内濃度（2例）は1.09, 









































53.5歳）で，体重は 42～75kg （平均 57kg）であっ
た（Table1). 






Table 1. Clinical summary of the patients prevented with Amphotercin B 












T.Y. 53 M 
W.N. 55 M 
K.M. 43 F 
T.I 49 M 
’ 
l.H. 75 M 
S.T. 53 F 
H.W 66 M 
M.F. 38 M 
IS. 44 F 
K.K 60 M 
F.H 53 F 
OFLX : Ofloxaci「I p.O 
KM : Kanamycin p.o 














Underlying Amphotericin B Concomitant 
disease Total drug 
『ng×times×days Route （町市）
Hepatoma 2,400×2×3 14,400 P.O. OFLX 1800町噂／day
Hepatoma 2,400×2×3 14,400 P.O. KM O~／day OFLX 2 /day 
Hepatoma 2,400×2×3 14,400 P.O OFLX 60伽ig/day
Hepatoma 2,400×2×3 14,400 P.O. OFLX 60αng/day 
Hepatoma 2,400×2×3 14,400 P.O. OFLX 600mgiday 
Hepatoma 2,400×2×3 14,400 P.O. OFLX 600mg/day 
Hepatoma 2,400×2×3 14,400 P.O. OFLX 600mg/day 
He~~toma 
Va 2,400×2×3 14,400 P.O. KM 2g/day 
陶patolithia錨 2,400×2×3 14,400 P.O KM 2g/day 
Hepa tom a 2,400×2×3 14,400 P.O KM 2 g/day 
Cholangio-
2,400×2×3 14,400 P.O. OFLX 400mg/day carcinoma PIPC 4g /day 
Table 2. Method of administration and time of Sampling 
Preadminist- 1st day of 2nd day after 3rd day after consecutive consecutive 
ration administration administration administration 
AMPH AMPH AMPH 
Morning or or 。「
OFLX OFLX OFLX 
AMPH AMPH AMPH 
Evening or or 









AMPH : Amphotericin B 
KM : Kanamycin 
OFLX : Ofloxacin 

































は 1.20 ±0. 5 /Lg/mlであり， それぞれの最高値は
1. 00 /Lg/ g, 1. 95 /Lg/mlであった．
また，胆嚢壁が 0.76 /Lg/g，牌組織が0.56 JLg/gで
あり，手術日の血中濃度をlとした場合，肝組織，胆
嚢胆汁はそれぞれ5.8倍， 13.3倍であり，胆嚢壁，牌組
織もそれぞれ8.4倍， 6.2倍であった（Table3, Fig. l) 






AMPH最終投与4時間後の血中濃度は， Bioassay 投与1症例全例において，自・他覚的副作用， BUN,
で0.11±0.01 /Lg/ml (HPLCは 0.08土0.02 /Lg/ml) S-Cr, GOT, GPT, Al-Paseなどの臨床検査値異常を
であり，手術日は投与20時間後にも拘らず，それぞれ 認めなかった．
0.12士0.02 /Lg/ml (HPLCは0.09±0. 04 /Lg/ml）と，
Table 3. Amphotericin B concentrations in serum, liver, bile, gallbladder and spleen 
On the 3rd day 
On the day of surgery 
Case of adm1stration 
No Serum Serum Liver Bile Galblader Splen 
(μg/ml) (μgt『nl) (μgig) (μg/ml) (μgig) (μgig) 
0.09 0 .13 0.42 0.23 ＊ ＊ 
2 ＊ 0.10 0.42 ＊ ＊ ＊ 
3 0.07 0.07 0.66 1.80 ＊ ＊ 
4 0.08 0.07 0.50 1.95 ＊ ＊ 
5 ＊ 0.15 1.00 1.14 ＊ ＊ 
6 ＊ 0.07 0.42 ＊ ＊ ＊ 
7 0.08 0.13 0.46 1.05 ＊ ＊ 
8 ＊ 0.04 0.56 1.32 1.09 0.56 
9 0.10 0.06 0.56 1.38 ＊ ＊ 
10 ＊ 0.08 0.31 0.75 0.42 ＊ 
1 0.04 0.05 0.45 ＊ ＊ ＊ 
Mean+S.D. 0.08+0.02 0.09+0.04 0.52+0.18 1.20+0.55 0.76 0.56 
(n) ( 6) (11) (11) ( 8) ( 2) ( 1 ) 
Comparative叩ncent-
ration Index (serum 
0.9 5.8 13.3 8.4 6.2 concentration on the 
day of surgery = 1 ) 
Measured by HPLC 
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2.0 
serum Liver 町le Galblader Splen 









Fig. 1. Comparison of Amphotericin B concentrations in serum, liver, bile, gallbladder and spleen 
Table 4. Comparison of Amphotericin B concentrations by HPLC and Bioassay 
On the 3rd day of administration On the day of surgery 
Case 
HPLC No Bioassay HPLC Bioassay 
(μg/ml) (μg/ml) (μg/ml) (μg/ml) 
0.09 0.12 0.13 0.12 
3 0.07 0.12 0.07 0.15 
4 0.08 ＊ 0.07 0.11 
7 0.08 0.09 0.13 ＊ 
9 0.10 ＊ 0.06 ＊ 
1 0.04 0.11 0.05 0.11 
Mean+S.D. 
0.08±0.02 0.11±0.01 0.09±0.01 0.12±0.02 
(6) (4) (6) (4) 
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考察












































































































































































うかがえた. Candida albi・cansの MICaoが 0.15μ.g/ 
mlである乙とから，肝・胆道系および牌など網内系
における AMPHの濃度は MICaoを十分に超える乙
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